Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 11Thoracic 7Gastrointestinal 4Genitourinary 3CNS 3Breast 3Gynecologic 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Dermatologic 1

Conditions

Ovarian Neoplasms 2Recurrence 1Peritoneal Neoplasms 1Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma 1

Interventions

Paclitaxel 153Carboplatin 123Bevacizumab 88Cisplatin 66pembrolizumab 58Taxes 51Gemcitabine 51liposomal doxorubicin 39Topotecan 37olaparib 32Immunoglobulin G 27Disulfides 26Cyclophosphamide 24Brachytherapy 22Docetaxel 21human papillomavirus vaccine, L1 type 16, 18 20niraparib 19Platinum 19Nivolumab 18Magnetic Resonance Spectroscopy 181,2-diaminocyclohexaneplatinum II citrate 18rucaparib 17durvalumab 17Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 16Doxorubicin 16Radiotherapy, Intensity-Modulated 14Radiation 13Albumin-Bound Paclitaxel 13fludarabine phosphate 12fludarabine 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × enzastaurin × Gynecologic × Clear all
NCT00420381 2020-12-19

Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer

Eli Lilly and Company

Phase 2 Completed
28 enrolled 13 charts
Gynecologic

Carcinoma, Neoplasms, Ovarian Neoplasms, Recurrence

NCT00391118 2020-10-19

Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill")

Eli Lilly and Company

Phase 2 Completed
153 enrolled 20 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡